| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/CIRCULATIONAHA.114.013748 |
| P698 | PubMed publication ID | 25403646 |
| P50 | author | Milton Packer | Q30314921 |
| Sergey Boytsov | Q42872234 | ||
| John McMurray | Q56633150 | ||
| Michele Senni | Q57060865 | ||
| Karl Swedberg | Q65769660 | ||
| Michael R Zile | Q78851222 | ||
| Randall C Starling | Q87210023 | ||
| Iain Squire | Q87617143 | ||
| John R Teerlink | Q90422543 | ||
| Arend Mosterd | Q97594396 | ||
| Felix José Alvarez Ramires | Q100484496 | ||
| Jean Rouleau | Q111842949 | ||
| Victor C Shi | Q114321829 | ||
| Adel R Rizkala | Q114321844 | ||
| Ömer Kozan | Q114443549 | ||
| Johan Vanhaecke | Q114443550 | ||
| Marta Negrusz-Kawecka | Q124845773 | ||
| P2093 | author name string | Walter Cabrera | |
| Jun Huang | |||
| Jan Bělohlávek | |||
| Dragos Vinereanu | |||
| Akshay S Desai | |||
| Scott D Solomon | |||
| Michael Böhm | |||
| Songsak Kiatchoosakun | |||
| Chen-Huan Chen | |||
| Lesley J Burgess | |||
| Karl Andersen | |||
| Kee-Sik Kim | |||
| Felipe Martinez | |||
| Keijo Peuhkurinen | |||
| Bela Merkely | |||
| Carlos Calvo | |||
| Raymond Ching-Chiew Wong | |||
| J Malcolm Arnold | |||
| Michael Fu | |||
| Andrej Dukat | |||
| Martin P Lefkowitz | |||
| Andrejs Erglis | |||
| Efrain Gomez | |||
| Yan Carlos Duarte | |||
| Albert A Hagège | |||
| Jens Refsgaard | |||
| José Silva-Cardoso | |||
| Tzvetana Katova | |||
| Antonio S Sibulo | |||
| Iván Mendoza | |||
| Jianjian Gong | |||
| Juan Luis Arango | |||
| Arvo Rosenthal | |||
| Angel Gonzàlez-Medina | |||
| Edmundo Bayram Llamas | |||
| PARADIGM-HF Investigators and Coordinators | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| heart failure | Q181754 | ||
| enalapril | Q422185 | ||
| P304 | page(s) | 54-61 | |
| P577 | publication date | 2014-11-17 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure | |
| P478 | volume | 131 |
| Q55311599 | A New Mechanism of Action in Heart Failure: Angiotensin-Receptor Neprilysin Inhibition. |
| Q26770151 | A Test in Context: Critical Evaluation of Natriuretic Peptide Testing in Heart Failure |
| Q58796635 | A comparison of the prognostic value of BNP versus NT-proBNP after hospitalisation for heart failure |
| Q41083010 | ANMCO/ELAS/SIBioC Consensus Document: biomarkers in heart failure. |
| Q90155608 | ARNIs: balancing "the good and the bad" of neuroendocrine response to HF |
| Q91610774 | ARNi: A Novel Approach to Counteract Cardiovascular Diseases |
| Q59826606 | Abstracts from the 7th International Conference on cGMP Generators, Effectors and Therapeutic Implications |
| Q38534772 | Angiotensin II Receptor Blocker Neprilysin Inhibitor (ARNI): New Avenues in Cardiovascular Therapy. |
| Q46770238 | Angiotensin Receptor-Neprilysin Inhibition |
| Q38790076 | Angiotensin receptor neprilysin inhibitor LCZ696: pharmacology, pharmacokinetics and clinical development |
| Q38982213 | Angiotensin-Neprilysin Inhibition as a Paradigm for All? |
| Q89335175 | Assessment of Drug-Drug Interaction Potential Between Atorvastatin and LCZ696, A Novel Angiotensin Receptor Neprilysin Inhibitor, in Healthy Chinese Male Subjects |
| Q36069585 | Association of pre-ablation level of potential blood markers with atrial fibrillation recurrence after catheter ablation: a meta-analysis |
| Q92127154 | BNP as a Major Player in the Heart-Kidney Connection |
| Q92134453 | Beneficial effects of sacubitril/valsartan in heart failure with reduced ejection fraction: pas à cause du BNP? |
| Q38773708 | Biochemistry, Therapeutics, and Biomarker Implications of Neprilysin in Cardiorenal Disease. |
| Q39127729 | Biomarkers of Heart Failure with Preserved and Reduced Ejection Fraction. |
| Q55363721 | Brain Natriuretic Peptide and Its Biochemical, Analytical, and Clinical Issues in Heart Failure: A Narrative Review. |
| Q87904516 | Can 2 Pills a Day Keep Readmission Away?: Sacubitril/Valsartan to Reduce 30-Day Heart Failure Readmissions |
| Q38967512 | Can Natriuretic Peptides be Used to Guide Therapy? |
| Q57161306 | Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease |
| Q95660687 | Cardiac natriuretic peptides |
| Q39373350 | Cardiac resynchronization therapy and its role in the management of heart failure |
| Q92528676 | Cardiovascular Pleiotropic Effects of Natriuretic Peptides |
| Q92058675 | Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial |
| Q36860608 | Cenderitide: structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancing in vivo and ex vivo actions |
| Q37597972 | Changing the treatment of heart failure with reduced ejection fraction: clinical use of sacubitril-valsartan combination |
| Q38987185 | Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy |
| Q39247505 | Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor |
| Q92095068 | Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction |
| Q40000430 | Combining angiotensin II receptor 1 antagonism and neprilysin inhibition for the treatment of heart failure |
| Q26741029 | Critical Questions about PARADIGM-HF and the Future |
| Q88863380 | Current Understanding of the Compensatory Actions of Cardiac Natriuretic Peptides in Cardiac Failure: A Clinical Perspective |
| Q92581382 | Cyclic Guanosine Monophosphate and Risk of Incident Heart Failure and Other Cardiovascular Events: the ARIC Study |
| Q37595978 | Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction |
| Q91862600 | Design, Synthesis, and Actions of an Innovative Bispecific Designer Peptide |
| Q48283568 | Developing Drugs for Heart Failure With Reduced Ejection Fraction: What Have We Learned From Clinical Trials? |
| Q38709338 | Diabetic Kidney Disease in Adolescents With Type 2 Diabetes: New Insights and Potential Therapies |
| Q90109076 | Differential Regulation of ANP and BNP in Acute Decompensated Heart Failure: Deficiency of ANP |
| Q91173761 | Discovery of Novel Multi-target Inhibitor of angiotensin type 1 receptor and neprilysin inhibitors from Traditional Chinese Medicine |
| Q36003962 | Discovery of novel small molecule inhibitors of cardiac hypertrophy using high throughput, high content imaging |
| Q35101841 | Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice |
| Q33751504 | Drug-Induced Inhibition of Angiotensin Converting Enzyme and Dipeptidyl Peptidase 4 Results in Nearly Therapy Resistant Bradykinin Induced Angioedema: A Case Report |
| Q34485114 | Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM. |
| Q41968416 | Early activation of deleterious molecular pathways in the kidney in experimental heart failure with atrial remodeling |
| Q93049471 | Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial |
| Q50047833 | Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). |
| Q48273577 | Effect of the angiotensin receptor neprilysin inhibitor sacubitril/valsartan on pharmacokinetics and pharmacodynamics of a single-dose of furosemide. |
| Q88264376 | Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial |
| Q90300274 | Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study |
| Q53035483 | Efficacy and Safety of Sacubitril/Valsartan (LCZ696) Compared With Olmesartan in Elderly Asian Patients (≥65 Years) With Systolic Hypertension. |
| Q36128797 | Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. |
| Q64273291 | Efficacy of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor-Neprilysin Inhibitors in the Treatment of Chronic Heart Failure: A Review of Landmark Trials |
| Q58776088 | Entresto therapy effectively protects heart and lung against transverse aortic constriction induced cardiopulmonary syndrome injury in rat |
| Q50634411 | Erratum to: Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor. |
| Q38781645 | First-in-Class Composite Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Practice |
| Q39011741 | Focus on the Novel Cardiovascular Drug LZC696: from Evidence to Clinical Consideration |
| Q28073372 | From ARB to ARNI in Cardiovascular Control |
| Q38780801 | From Bench to Bedside: New Approaches to Therapeutic Discovery for Heart Failure |
| Q91382159 | Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial |
| Q92925812 | Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations |
| Q39036794 | Heart failure - what's new and what's changed? |
| Q47307328 | Heart failure - what's new and what's changed? |
| Q38307955 | Heart failure therapies in 2014: Mixed results for heart failure therapies |
| Q38754215 | Heart failure trials on pharmacological therapy in 2015: lessons learned and future outlook |
| Q86101179 | Heart failure: another new PARADIGM in treatment for heart failure? |
| Q92446745 | How does neprilysin inhibition in heart failure work? |
| Q91881990 | I Kid(ney) You Not...Natriuretic Peptides Which Promote Natriuresis but Not Hypotension |
| Q52660241 | Impact of prolonged utilization of neprilysin inhibition on the cognitive function of heart failure patients. |
| Q47700110 | Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study. |
| Q39029773 | Importance of endogenous compensatory vasoactive peptides in broadening the effects of inhibitors of the renin-angiotensin system for the treatment of heart failure. |
| Q57396162 | Improving outcomes in heart failure: a personal perspective |
| Q92331843 | Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study |
| Q91837383 | Initiation of sacubitril/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study |
| Q49718855 | Insights into implementation of sacubitril/valsartan into clinical practice |
| Q90482640 | Intensive care for human hearts in pluripotent stem cell models |
| Q38924076 | Kicking the tyres of a heart failure trial: physician response to the approval of sacubitril/valsartan in the USA. |
| Q41686228 | Korean Guidelines for Diagnosis and Management of Chronic Heart Failure. |
| Q38568202 | LCZ696 (Valsartan/Sacubitril)--A Possible New Treatment for Hypertension and Heart Failure. |
| Q53586435 | LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone. |
| Q96350494 | Looking at the heart failure through the prism of liver dysfunction |
| Q38709514 | Mechanisms of action of sacubitril/valsartan on cardiac remodeling: a systems biology approach. |
| Q41102306 | MiR30-GALNT1/2 Axis-Mediated Glycosylation Contributes to the Increased Secretion of Inactive Human Prohormone for Brain Natriuretic Peptide (proBNP) From Failing Hearts |
| Q33862358 | Natriuretic Peptides as Biomarkers for Congestive States: The Cardiorenal Divergence |
| Q64233573 | Natriuretic Peptides in Chronic Heart Failure |
| Q38837698 | Natriuretic peptides as biomarkers of cardiac endocrine function in heart failure: new challenges and perspectives. |
| Q34495751 | Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review |
| Q38968534 | Neprilysin Inhibitors in Cardiovascular Disease |
| Q38853482 | Neprilysin and Natriuretic Peptide Regulation in Heart Failure |
| Q39192295 | Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides. |
| Q27027707 | Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances |
| Q38780567 | Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck |
| Q89654136 | Neprilysin inhibition, endorphin dynamics, and early symptomatic improvement in heart failure: a pilot study |
| Q38817943 | Neprilysin inhibition: A brief review of past pharmacological strategies for heart failure treatment and future directions |
| Q48352528 | Neprilysin, cardiovascular, and Alzheimer's diseases: the therapeutic split? |
| Q93036855 | Neprilysin: A Potential Therapeutic Target of Arterial Hypertension? |
| Q88711774 | Neurohormonal Blockade in Heart Failure |
| Q38738871 | New and old agents in the management of diabetic nephropathy |
| Q38429870 | New developments in the pharmacological treatment of hypertension: dead-end or a glimmer at the horizon? |
| Q38594785 | New medical therapies for heart failure |
| Q38546656 | New medications for heart failure |
| Q89447793 | New pharmacological treatments for heart failure with reduced ejection fraction (HFrEF): A Bayesian network meta-analysis |
| Q104466344 | OUTSTEP-HF: Randomised controlled trial comparing short-term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction |
| Q90322186 | Optimizing heart failure treatment following cardiac resynchronization therapy |
| Q52954530 | Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats. |
| Q90393579 | Patients report more severe daily limitations than recognized by their physicians |
| Q87430670 | Pharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese Subjects |
| Q89304755 | Pharmacologic Management of Cancer Therapeutics-Induced Cardiomyopathy in Adult Cancer Survivors |
| Q26765883 | Pharmacological Therapy in the Heart as an Alternative to Cellular Therapy: A Place for the Brain Natriuretic Peptide? |
| Q89903377 | Pharmacological interventions for heart failure in people with chronic kidney disease |
| Q90626796 | Practical guidance on the use of sacubitril/valsartan for heart failure |
| Q58704486 | Predictive value of soluble ST-2 for changes of cardiac function and structure in breast cancer patients receiving chemotherapy |
| Q28077186 | Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm |
| Q36054705 | Pro-Atrial Natriuretic Peptide: A Novel Guanylyl Cyclase-A Receptor Activator That Goes Beyond Atrial and B-Type Natriuretic Peptides |
| Q42373826 | Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives |
| Q99573052 | Prognostic value of brain natriuretic peptide vs history of heart failure hospitalization in a large real-world population |
| Q39317320 | Progress in the Presence of Failure: Updates in Chronic Systolic Heart Failure Management |
| Q35842030 | Racial Differences in Natriuretic Peptide Levels: The Dallas Heart Study. |
| Q89831120 | Racial/ethnic differences in circulating natriuretic peptide levels: The Diabetes Prevention Program |
| Q49848555 | Rationale and design of TRANSITION: a randomized trial of pre-discharge vs. post-discharge initiation of sacubitril/valsartan |
| Q104284282 | Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling |
| Q39410727 | Rationales and choices for the treatment of patients with NYHA class II heart failure |
| Q94585840 | Reappraisal on pharmacological and mechanical treatments of heart failure |
| Q26766223 | Recent advances in treatment of heart failure |
| Q48369499 | Regulation of circulating chromogranin B levels in heart failure. |
| Q92666233 | Relation between therapy-induced changes in natriuretic peptide levels and long-term therapeutic effects on mortality in patients with heart failure and reduced ejection fraction |
| Q58094858 | Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period |
| Q38854043 | Resetting the neurohormonal balance in heart failure (HF): the relevance of the natriuretic peptide (NP) system to the clinical management of patients with HF |
| Q26746907 | Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies |
| Q38871148 | Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure |
| Q38614176 | Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use. |
| Q36736998 | Sacubitril Is Selectively Activated by Carboxylesterase 1 (CES1) in the Liver and the Activation Is Affected by CES1 Genetic Variation |
| Q42564219 | Sacubitril/Valsartan |
| Q57396137 | Sacubitril/Valsartan (LCZ696) in Heart Failure |
| Q90583568 | Sacubitril/Valsartan (LCZ696): A Novel Treatment for Heart Failure and its Estimated Cost Effectiveness, Budget Impact, and Disease Burden Reduction in Germany |
| Q38731859 | Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction |
| Q89443547 | Sacubitril/Valsartan: potential treatment for paediatric heart failure |
| Q38661061 | Sacubitril/valsartan (LCZ696) for the treatment of heart failure. |
| Q92609621 | Sacubitril/valsartan and B-type natriuretic peptide value: recalculating route |
| Q92315509 | Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world |
| Q95354713 | Sacubitril/valsartan in PARADIGM-HF |
| Q64327462 | Sacubitril/valsartan in cardiovascular disease: evidence to date and place in therapy |
| Q28070191 | Sacubitril/valsartan in heart failure: latest evidence and place in therapy |
| Q47691038 | Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF. |
| Q38752308 | Screening echocardiograms in a senior focused value based primary care improves systolic heart failure detection and clinical management |
| Q41628214 | Serum Neprilysin and Recurrent Admissions in Patients With Heart Failure. |
| Q88711658 | Should Angiotensin Receptor Neprilysin Inhibitors Replace Angiotensin-converting Enzyme Inhibitors in Heart Failure With a Reduced Ejection Fraction? |
| Q33578212 | Silent disease progression in clinically stable heart failure |
| Q39579918 | Six-Year Change in High-Sensitivity Cardiac Troponin T and Risk of Subsequent Coronary Heart Disease, Heart Failure, and Death |
| Q92179630 | Soluble Neprilysin in the General Population: Clinical Determinants and Its Relationship to Cardiovascular Disease |
| Q28070064 | Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date |
| Q88673406 | Stable but Progressive Nature of Heart Failure: Considerations for Primary Care Physicians |
| Q95651532 | StatinImplications of the complex biology and micro-environment of cardiac sarcomeres in the use of high affinity troponin antibodies as serum biomarkers for cardiac disorders |
| Q47855200 | Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure |
| Q50913357 | Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. |
| Q38568205 | The Current and Potential Clinical Relevance of Heart Failure Biomarkers |
| Q88711653 | The Mechanism of Action of LCZ696 |
| Q42700358 | The Role of Neprilysin Inhibitors in Cardiovascular Disease |
| Q38558614 | The Three-Decade Long Journey in Heart Failure Drug Development |
| Q48136990 | The dark side of the kidney in cardio-renal syndrome: renal venous hypertension and congestive kidney failure. |
| Q41549636 | The evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril/valsartan |
| Q37583865 | The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment |
| Q41549509 | The need to apply the best therapy in heart failure - the era after PARADIGM-HF. |
| Q26747165 | The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan |
| Q38551693 | The potential role of natriuretic peptides and other biomarkers in heart failure diagnosis, prognosis and management |
| Q90405796 | The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes |
| Q48230309 | The renal and cardiovascular effects of natriuretic peptides |
| Q49719494 | The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions |
| Q89537348 | Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan |
| Q60943112 | Updates in heart failure: what last year brought to us |
| Q45070171 | Use of sacubitril/valsartan in acute decompensated heart failure: a case report |
| Q38613842 | Using biomarkers to guide heart failure management |
| Q52581574 | What Is New in Heart Failure Management in 2017? Update on ACC/AHA Heart Failure Guidelines. |
| Q40116429 | Will sacubitril-valsartan diminish the clinical utility of B-type natriuretic peptide testing in acute cardiac care? |
| Q52821448 | [Acute and chronic heart failure]. |
| Q85404538 | [Chronic heart failure : current guideline recommendations and innovations] |
| Q89184276 | [Essential cardiac biomarkers in the differential diagnosis of acute chest pain : An update] |
| Q53194483 | [New pharmacologic therapies for chronic heart failure]. |
| Q85512879 | [Update on therapy of chronic heart failure. Innovations and studies from last year] |
Search more.